Akero Therapeutics (NASDAQ:AKRO) Given New $75.00 Price Target at HC Wainwright

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) had its price target hoisted by equities researchers at HC Wainwright from $72.00 to $75.00 in a report released on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 71.74% from the stock's previous close. HC Wainwright also issued estimates for Akero Therapeutics' Q1 2025 earnings at ($0.96) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at ($4.55) EPS, FY2027 earnings at ($4.19) EPS, FY2028 earnings at ($2.95) EPS and FY2029 earnings at $2.67 EPS.

Other research analysts have also recently issued research reports about the company. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Citigroup raised their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Morgan Stanley upped their target price on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Canaccord Genuity Group lifted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Finally, UBS Group boosted their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $76.29.

Remove Ads

Akero Therapeutics Price Performance

NASDAQ:AKRO traded down $1.46 during trading hours on Monday, hitting $43.67. The stock had a trading volume of 915,848 shares, compared to its average volume of 868,183. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of -11.65 and a beta of -0.19. Akero Therapeutics has a one year low of $17.86 and a one year high of $58.40. The company has a 50 day simple moving average of $39.92 and a two-hundred day simple moving average of $33.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Research analysts forecast that Akero Therapeutics will post -3.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, VP Patrick Lamy sold 925 shares of the company's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total value of $28,480.75. Following the sale, the vice president now owns 17,858 shares in the company, valued at approximately $549,847.82. This represents a 4.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Jonathan Young sold 10,000 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00. Following the sale, the chief operating officer now directly owns 218,083 shares in the company, valued at approximately $6,112,866.49. The trade was a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 224,992 shares of company stock worth $10,800,953. Company insiders own 7.94% of the company's stock.

Institutional Trading of Akero Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new stake in Akero Therapeutics in the fourth quarter valued at $41,000. Sterling Capital Management LLC raised its holdings in Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after buying an additional 1,582 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock valued at $71,000 after buying an additional 446 shares during the last quarter. Quarry LP purchased a new position in Akero Therapeutics during the fourth quarter worth about $83,000. Finally, Summit Investment Advisors Inc. increased its position in shares of Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after acquiring an additional 450 shares during the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.